Clinical Trials Sponsored by Allecra

Total 67 results

Allecra

Completed

Pharmacokinetics of Cefepime and AAI101 in Subjects With Renal Insufficiency and Healthy Subjects

PK in Patients With Various Degrees of Renal Impairment

Czechia, Hungary
Allecra

Completed

Investigation of AAI101 Safety, Tolerability & PK in Healthy Volunteers

Healthy
Allecra

Completed

Single Dose Mass Balance Study With C14 - Labeled AAI101 in Healthy Male Volunteers

Healthy

United States
Allecra

Completed

Lung Pharmacokinetics (PK) in Epithelial Lining Fluid (ELF)

Healthy Subjects

United Kingdom
Allecra
Medpace, Inc.

Completed

Safety and Efficacy Study of Cefepime-AAI101 in the Treatment of Complicated Urinary Tract Infections

Urinary Tract Infections

United States, Serbia, Hungary, Estonia, South Africa, Belarus, Poland, Ukraine, Argentina, Bulgaria, Croatia, Georgia, Latvia, Lithuania, Mexico, Peru, Russian Federation, Slovakia, Spain
Allecra
Medpace, Inc.

Completed

Cefepime/AAI101 Phase 2 Study in Hospitalized Adults With cUTI

Urinary Tract Infections

Hungary, Czechia, Poland, Slovakia, Ukraine
Allecra
Linical Co., Ltd.

Recruiting

A Study to Investigate PK, Safety, Tolerability of Cefepime-enmetazobactam in Pediatric Participants With cUTI

Complicated Urinary Tract Infection

Spain, France, Czechia, Hungary, Poland, Slovakia
Allena Pharmaceuticals

Completed

An Inpatient Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects (Study 201)

Chronic Kidney Diseases | Hyperuricemia | Gout

United States
Allena Pharmaceuticals

Terminated

Establishing the Safety and Efficacy of Reloxaliase in Patients With Enteric Hyperoxaluria (URIROX-2)

Enteric Hyperoxaluria

United States, Spain, United Kingdom, Portugal, Romania, Canada, Austria, Belgium, Brazil, Croatia, France, Germany, Italy, Mexico, Russian Federation, Switzerland
Aldeyra Therapeutics, Inc.

Recruiting

A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)

Atopic Dermatitis

United States
Aldeyra Therapeutics, Inc.

Completed

The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease

Dry Eye

United States
Aldeyra Therapeutics, Inc.

Completed

A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety and Efficacy of Subjects With Mild Asthma Induced by the Bronchial Allergen Challenge (BAC)

Atopic Asthma

Canada
Aldeyra Therapeutics, Inc.

Completed

The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease

Dry Eye | Dry Eye Syndromes

United States
Aldeyra Therapeutics, Inc.

Completed

The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis.

Allergic Conjunctivitis

Canada
Aldeyra Therapeutics, Inc.

Completed

The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease

Dry Eye

United States
Aldeyra Therapeutics, Inc.

Completed

A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis

Allergic Conjunctivitis

United States
Aldeyra Therapeutics, Inc.

Completed

A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye Disease

Dry Eye

United States
Allegro Ophthalmics, LLC

Withdrawn

Safety Study of ALG- 1001 to Treat Diabetic Macular Edema

Diabetic Macular Edema

Mexico
Allena Pharmaceuticals

Terminated

Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease

Chronic Kidney Diseases | Hyperuricemia | Gout

United States
Allena Pharmaceuticals

Completed

A Pilot Study of Oxalate Absorption in Secondary Hyperoxaluria

Nephrolithiasis | Kidney Stones | Hyperoxaluria | Secondary Hyperoxaluria

United States
Allena Pharmaceuticals

Completed

Study 102: Multiple Ascending Dose Study of ALLN-346 (Engineered Urate Oxidase) (MAD)

Hyperuricemia | Gout

United States
Allena Pharmaceuticals

Completed

Study of ALLN-177 in Patients Aged 12 Years or Older With Enteric or Primary Hyperoxaluria and Hyperoxalemia

Enteric Hyperoxaluria | Primary Hyperoxaluria | Hyperoxalemia

United States, United Kingdom, Germany
Allena Pharmaceuticals

Completed

Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Hyperoxaluria and Kidney Stones

Nephrolithiasis | Kidney Stones | Hyperoxaluria | Secondary Hyperoxaluria | Dietary Hyperoxaluria

United States
Allena Pharmaceuticals

Completed

ALLN-346 Single Ascending Dose (SAD) Study in Healthy Volunteers (SAD)

Hyperuricemia

United States
Allena Pharmaceuticals

Completed

Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria

Enteric Hyperoxaluria

United States, Spain, United Kingdom, Germany, Canada, Italy, France
Allena Pharmaceuticals

Completed

Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hyperoxaluria

Nephrolithiasis | Hyperoxaluria

United States
Allena Pharmaceuticals

Completed

Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Secondary Hyperoxaluria and Kidney Stones Over 28 Days

Nephrolithiasis | Kidney Stones | Hyperoxaluria | Secondary Hyperoxaluria | Dietary Hyperoxaluria

United States
Aldeyra Therapeutics, Inc.

Completed

A Study in Subjects With Retinitis Pigmentosa

Retinitis Pigmentosa

United States
Aldeyra Therapeutics, Inc.

Completed

The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis

Allergic Conjunctivitis

Canada
Aldeyra Therapeutics, Inc.

Completed

A Safety and Activity Study of NS2 in Subjects With Allergic Conjunctivitis

Allergic Conjunctivitis | Seasonal Allergies

Canada
Aldeyra Therapeutics, Inc.

Completed

A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease

Dry Eye Disease

United States
Aldeyra Therapeutics, Inc.

Completed

A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis

Non-infectious Anterior Uveitis

United States
Aldeyra Therapeutics, Inc.

Completed

RESET Trial - Part 1 - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS)

Sjogren-Larsson Syndrome

United States
Aldeyra Therapeutics, Inc.

Completed

A Clinical Trial to Evaluate the Safety and Efficacy of Rreproxalap in Adults With Dry Eye Disease

Dry Eye Syndromes

Canada
Aldeyra Therapeutics, Inc.

Completed

An Exploratory Clinical Trial to Assess Safety and Tolerability in Subjects With Dry Eye Disease

Dry Eye

Canada
Aldeyra Therapeutics, Inc.

Completed

A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber

Conjunctivitis, Allergic

Canada
Allegro Ophthalmics, LLC

Completed

A Safety And Efficacy Study Of Alg-1001 In Human Subjects With Symptomatic Focal Vitreomacular Adhesion

Symptomatic Focal Vitreomacular Adhesion

United States
Allegro Ophthalmics, LLC

Completed

A Safety And Efficacy Study Of ALG-1001 In Human Subjects With Wet Age-Related Macular Degeneration

Macular Degeneration

Mexico
Aldeyra Therapeutics, Inc.

Withdrawn

Part 1 - A Clinical Trial in Patients With Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome

Nephrotic Syndrome

United States
Aldeyra Therapeutics, Inc.

Completed

A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic Cough

Chronic Cough

United States
Aldeyra Therapeutics, Inc.

Completed

The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy

Proliferative Vitreoretinopathy

United States
Aldeyra Therapeutics, Inc.

Completed

A Clinical Trial to Assess Subjects With Dry Eye Disease.

Dry Eye

United States
Aldeyra Therapeutics, Inc.

Completed

A Clinical Trial to Evaluate the Safety and Efficacy of ADX-629 in in Subjects With Elevated Ethanol Levels

Ethanol Intoxication

United States
Aldeyra Therapeutics, Inc.

Completed

A Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Subjects With Plaque Psoriasis

Plaque Psoriasis

United States
Aldeyra Therapeutics, Inc.

Completed

A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)

Sjögren-Larsson Syndrome

United States
Aldeyra Therapeutics, Inc.

Completed

A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics for the Treatment of COVID-19.

Covid19

United States
Allegro Ophthalmics, LLC

Completed

A Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of 1.0 Mg Luminate® (Alg-1001) As A Treatment For Non-Exudative Macular Degeneration

Dry Age-related Macular Degeneration

United States
Aldeyra Therapeutics, Inc.

Completed

SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.

Non-infectious Anterior Uveitis

United States
Aldeyra Therapeutics, Inc.

Completed

ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis

Allergic Conjunctivitis

United States
Aldeyra Therapeutics, Inc.

Completed

A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease

Dry Eye Syndrome

United States

3

Subscribe